Opna Bio
Opna Bio is a clinical-stage biopharmaceutical company focused on discovering and developing oncology treatments that target key regulators of cancer. The company's pipeline includes OPN-6602, an EP300 inhibitor for multiple myeloma, and zavabresib, a BET inhibitor for myelofibrosis. Their research also extends to multi-functional degraders and FMRP inhibitors for solid tumors and hematologic malignancies.
Visit websiteSouth San Francisco, United States
Biotechnology
Oncology
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €37.0M
- Funding rounds
- 1
Investors in Opna Bio
Investors on record for Opna Bio. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Opna Bio?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors